Centers of Cancer Nanotechnology Excellence (CCNEs)
The multi-disciplinary CCNE teams are the main venue for the discovery and tool development toward the application of nanotechnology to clinical oncology. CCNE teams are focused on integrated technology solutions and the aggressive development of these solutions from pre-clinical to clinical application. CCNEs are designed to enable multi-disciplinary team research by linking physical scientists, engineers and technologists working at the nanoscale with cancer biologists and oncologists specializing in the diagnosis, prevention and treatment of cancer.
Center of Cancer Nanotechnology Excellence for Translational Diagnostics
Principal Investigators: Sanjiv Sam Gambhir, M.D., Ph.D., and Shan Wang, Ph.D.
Scientific Focus: Our overarching focus is to develop and utilize in vitro nanosensors and in vivo molecular imaging tools to advance methods in earlier detection of aggressive cancers as well as monitoring response to therapy for both prostate and lung cancers.
Center for Multiple Myeloma Nanotherapy
Principal Investigators: Samuel Achilefu, Ph.D., and Gregory Lanza, M.D., Ph.D.
Scientific Focus: Multiple myeloma is a cancer of the bone marrow and although most patients respond well to initial chemotherapy, nearly all patients will eventually relapse and do not survive. Our primary objective is the development of nanoptherapeutics via unique drug delivery mechanisms and multidimensional treatment paradigms as well as noninvasive imaging methods to monitor subsequent treatment response for multiple myeloma.
MSKCC-Cornell Center for Translation of Cancer Nanomedicine
Memorial Sloan Kettering and Cornell University
Principal Investigators: Michelle Bradbury, M.D., Ph.D., and Ulrich Wiesner, Ph.D.
Scientific Focus: Our focus is to advance, translate, and disseminate a suite of ultrasmall (<10 nm) silica-organic hybrid nanoparticles with tunable size, brightness, and geometry. These will be utilized in the development and implementation of intraoperative optical detection tools to improve cancer localization, staging, and treatment, as well as the development of optimized therapeutic platforms for melanoma and malignant brain tumors.
Nano Approaches to Modulate Host Cell Response for Cancer Therapy
University of North Carolina
Principal Investigators: Leaf Huang, Ph.D., and Joel Tepper, M.D.
Scientific Focus: Host response targeting of both immune and stromal components, represents a game changing opportunity to overcome cancer through the body's own defense mechanisms. Our focus is to exploit the host response through nanotechnology-based approaches for cancer disease management and treatment of melanoma and non-small cell lung cancers (NSCLC).
Nanosystems Biology Cancer Center (NSBCC)
California Institute of Technology and University of California, Los Angeles
Principal Investigators: Jim Heath, Ph.D., and Michael Phelps, Ph.D.
Scientific Focus: Our focus lies in overcoming the challenges associated in both cancer immunotherapy and targeted therapy treatments via nanotechnology. As such, we focus on the design / development of nanotherapies and nanotech tools to guide selection of combination cancer immunotherapy and targeted therapy treatments for brain cancers and melanoma.
Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer
Principal Investigators: Chad Mirkin, Ph.D., and Leonidas Platanias, M.D., Ph.D.
Scientific Focus: Our focus centers upon the design, synthesis, characterization, and development of spherical nucleic acid constructs as effective nanotherapeutic, single-entity agents for the treatment of glioblastoma multiforme and prostate cancers.